Heart murmur: diagnostic tools Gasser, in his letter (April 1989 JRSM, p 245) failed to understand the purpose of my Editorial (September 1988 JRSM, p 501). The points I wanted cleared were and are:
(1)Clinical cardiologists should not evaluate a cardiac murmur, innocent or pathological, without using the stethoscope. The hallmark of a competent cardiologist is when he or she can inform the patient at the bedside or examining table that the murmur is innocent and no further testing is required. The reverse would be true for pathological murmurs.
(2) My Editorial deals strictly with the problem of systolic innocent or benign murmurs. Phonocardiography would be of great additional help in evaluating such murmurs, unfortunately it is not readily accessible.
(3) Using echocardiography with all its modalities in the routine evaluation of systolic innocent or benign cardiac murmurs is unacceptable, because it is not cost effective, it will only give you a negative result since the heart is basically 'normal', peer reviewers and quality assurance reviewers would frown upon such practice, the patient would resent paying a bill for normal findings, and in most instances a good history, physical examination with regularly half yearly or yearly follow-up scheduled visits would resolve the issue of such murmurs, and or phonocardiography. My Editorial does not suggest in the least that echocardiography should not be utilized for pathological murmurs, but that it does not add one iota in innocent murmurs. Finally, the routine sequence of cardiac diagnostic work up suggested by Gasser is not new and not his. Cardiac surgery, prior to echocardiography did exceptionally well, with only the clinical cardiac findings and cardiac catheterization data. The latter remains the 'golden' standard of cardiac haemodynamics. ME NASSAR Brockport, New York Role of chemotherapy in the management of oral cancer I read with interest McGregor's editorial on the management of intra-oral cancer (April 1989 JRSM, p 187). Although it provides a balanced view on the local management of advanced resectable intraoral cancers, the role of chemotherapy is not mentioned. Another point worth emphasizing is that radiotherapy results in local control and survival comparable with surgery in early lesions situated in the buccal mucosa, mucosal lip, floor of mouth and oral tongue with less morbidity and more cosmesis.
The role of chemotherapy in head and neck cancer has been recently reviewed by Choski et at. 1 and Al-Sarraf".
Systemic chemotherapy has been traditionally used in patients with recurrent and metastatic oral cancer who have failed to respond to definitive local treatment. The results of such salvage treatment have been reported to be disappointing and are of questionable value even from the point of palliation, considering the side effects and the cost benefit aspects. The complete response rates, often lasting for only a few weeks, achieved with both single agent and combination chemotherapy involving agents like methotrexate, bleomycin, 5-fluoro uracil and cisplatin have been less than 10%.
Even though many agree that the results achieved by radical surgery with or without radiotherapy are superior to that achieved by radical radiotherapy alone in patients with operable, advanced stage (III and IV) head and neck cancers, the frequency of recurrent disease after such treatment has been reported to be as high as 50-70%. Now chemotherapy is being evaluated in combined modality treatment to improve locoregional control, to reduce the frequency of distant metastases and to improve overall survival in advanced head and neck cancers. So far survival advantage has not been demonstrated in many studies, including randomized trials, assessing adjuvant chemotherapy of head and neck cancer and more studies are continuing.
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